Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.57 USD | +10.78% | +7.08% | +10.30% |
Apr. 04 | Transcript : VYNE Therapeutics Inc. - Special Call | |
Feb. 29 | VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Business Summary
Number of employees: 10
Managers
Managers | Title | Age | Since |
---|---|---|---|
David Domzalski
CEO | Chief Executive Officer | 58 | 20-02-29 |
Tyler Zeronda
DFI | Director of Finance/CFO | 38 | - |
Iain Stuart
CTO | Chief Tech/Sci/R&D Officer | 51 | 20-02-29 |
Mutya Harsch
LAW | General Counsel | 50 | 20-02-29 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Pat LePore
BRD | Director/Board Member | 69 | 20-09-09 |
Steven Basta
BRD | Director/Board Member | 59 | 14-12-31 |
Anthony Bruno
BRD | Director/Board Member | 68 | 20-02-29 |
Director/Board Member | 62 | 19-02-28 | |
David Domzalski
CEO | Chief Executive Officer | 58 | 20-02-29 |
Director/Board Member | - | Dec. 31 | |
Sharon Barbari
BRD | Director/Board Member | 70 | 20-02-29 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 14,098,888 | 12,874,235 ( 91.31 %) | 0 | 91.31 % |
Company contact information
VYNE Therapeutics, Inc.
685 Route 202/206 North Suite 301
08807, Bridgewater
+
http://www.vynetherapeutics.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.30% | 32.71M | |
+25.61% | 672B | |
+25.87% | 570B | |
-5.24% | 360B | |
+16.49% | 321B | |
+8.28% | 300B | |
+7.09% | 217B | |
-9.12% | 204B | |
+5.01% | 199B | |
-8.75% | 149B |
- Stock Market
- Equities
- VYNE Stock
- Company VYNE Therapeutics Inc.